Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a “one-stop shop” for Big Pharma seeking mid-stage products to licence or acquire.
The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.
With its initial assets from Open Orphan plc, an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. It already has a Phase II ready repositioned small molecule immunomodulator for severe influenza and a portfolio of other exciting assets. The Company plans to broaden this portfolio further going forward and is in active discussions with AI data analysis platforms to help accelerate the power of its human challenge model data and biobank.
Visit the Poolbeg Pharma Plc website here
Follow Poolbeg Pharma on Twitter @PoolbegPharma
- #POLB Poolbeg Pharma – US patents granted for POLB 001 and POLB 002
- #POLB Poolbeg Pharma – TR-1: Notification of major interest in shares
- Alan Green covers Amaroq Minerals #AEXG and Poolbeg Pharma #POLB on this week’s Stockbox Research Talks
- #POLB Poolbeg Pharma – GMP manufacturing contract signed
- Poolbeg Pharma #POLB to engage with key international stakeholders at European Melioidosis Congress as it develops an intramuscular Melioidosis vaccine candidate
- Poolbeg Pharma #POLB presenting at LSX Leaders event
- Poolbeg Pharma #POLB – Results of the proposal to purchase shares from Distribution in Specie shareholders
- #POLB Poolbeg Pharma – Key POLB 002 European Patent Granted
- #POLB Poolbeg Pharma – Proposal to Purchase Shares from Distribution in Specie Shareholders
- #POLB Poolbeg Pharma – Result of AGM
- Poolbeg Pharma #POLB – POLB 001 Clinical Development – Clinical Trial Agreement Signed
- Poolbeg Pharma #POLB commences trading on OTCQB Market in the United States
- #POLB Poolbeg Pharma – Artificial Intelligence deal signed with CytoReason
- #ORPH Open Orphan – Open Orphan plc distribution in specie of Poolbeg Pharma plc shares – FAQ
- Alan Green covers #POLB Poolbeg Pharma, #NTOG Nostra Terra O&G and #MNRG MetalNRG on the Vox Market Podcast
- #POLB Poolbeg Pharma – POLB sign AI discovery deal with OneThree Biotech for first human challenge trial
- Poolbeg Pharma #POLB – 2021 Annual Report and 2022 AGM Notice
- #POLB Poolbeg Pharma – Final Results
- Poolbeg Pharma #POLB – Interview
- #POLB Poolbeg Pharma – Notice of Results
- #POLB Poolbeg Pharma – Artificial Intelligence deal with OneThree Biotech
- Poolbeg Pharma #POLB – Article – Further Assets
- Poolbeg Pharma #POLB – Upcoming London Webinar
- Poolbeg Pharma #POLB – sign licence agreement with AnaBio Technologies to develop oral vaccine platform
- #POLB Poolbeg Pharma – Confirmation of vaccine platform licence execution
- Vox Market Podcast – Alan Green discusses Revolution Bars #RGB, Blencowe Resources #BRES & Poolbeg Pharma #POLB
- Poolbeg Pharma #POLB – Licenses RNA-based immunotherapy asset
- Poolbeg Pharma #POLB – Growing a Capital Light Company. CEO Jeremy Skillington talks to Alan Green
- Pharma Times – Poolbeg Pharma dives into nasally administered antivirals
- #POLB Poolbeg Pharma – Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of Warwick
- Alan Green covers AEX Gold #AEXG and Poolbeg Pharma #POLB on this week’s Stockbox Research Talks
- Poolbeg Pharma #POLB CEO Jeremy Skillington talks to BRR Media
- #POLB Poolbeg Pharma – Poolbeg to develop oral vaccine delivery platform
- Poolbeg Pharma #POLB – Drug Discovery
- Poolbeg Pharma #POLB – agrees option agreement with UCD
- #POLB Poolbeg Pharma – Poolbeg signs option for new vaccine candidate
- #POLB Poolbeg Pharma – Shares Spotlight
- #POLB Poolbeg Pharma – Scientific Advisory Board Appointment
- #POLB Poolbeg Pharma – Update on POLB 001 Clinical Development
- Poolbeg Pharma #POLB – Exec Chairman Cathal Friel & CEO Jeremy Skillington talk to Alan Green
- Alan Green discusses ECR Minerals #ECR, with a tribute to CEO Craig Brown, plus Poolbeg Pharma #POLB on this week’s Stockbox Research talk
- #POLB Poolbeg Pharma – PredictViral™ Patent update
- Poolbeg Pharma #POLB – RNA sequencing ahead of AI analysis programme
- Poolbeg Pharma #POLB – Admission to AIM and First day of trading
- Open Orphan #ORPH – AIM Schedule 1 update by Poolbeg Pharma plc
- The Times – Our flu drug is not to be sniffed at, says Poolbeg Pharma chief Jeremy Skillington
